Account

New to ADSS? Open an
account now to get started.

OR

Already have an account?

Add funds to your ADSS account

Account

New to ADSS? Open an
account now to get started.

Add funds to your ADSS account

Trends & Analysis
News
Thor shares decline despite upbeat earnings
News
EUR/USD slides despite strong Germany data
News
Crude oil settles lower after surging past $82
News
S&P 500 declines despite upbeat NFP data
News
Kroger tops Q3 views amid steady grocery demand
News
XPeng shares skyrocket despite sales miss
Trends & Analysis
News
Thor shares decline despite upbeat earnings
News
EUR/USD slides despite strong Germany data
News
Crude oil settles lower after surging past $82
News
S&P 500 declines despite upbeat NFP data
News
Kroger tops Q3 views amid steady grocery demand
News
XPeng shares skyrocket despite sales miss

CFDs & spread bets are complex instruments & come with a high risk of losing money rapidly due to leverage. 72% of Retail investor accounts lose money when trading CFDs & spread bets with this provider. You should consider whether you understand how CFDs work & whether you can afford to take the high risk of losing your money.


Account
New to ADSS? Open an
account now to get started.
Open an account Login

News

Johnson & Johnson stock slides despite upbeat Q2

 

Wednesday, July 20, 2022, 8.45am GMT

The news shaping the markets today

Russia’s President Vladimir Putin had a meeting with Turkish President Recep Tayyip Erdogan and Iranian President Ebrahim Raisi, during his second foreign trip since the invasion of Ukraine. With hopes of some resolution, the safe-haven US dollar declined slightly this morning.


The People’s Bank of China maintained its one-year loan prime rate unchanged at 3.7%, sending the CNY/USD forex pair slightly lower.


Australia’s Westpac-Melbourne Institute Leading Economic Index fell by 0.2% year-over-year in June, following a 0.1% decline in the previous month. However, the AUD/USD pair rose in forex trading this morning.


Bitcoin prices surpassed the $23,000 level for the first time in over a month, with improving investor risk appetite globally.


Colombia’s trade deficit widened to $2.25 billion in May, from $1.28 billion in the year-ago month. The COP/USD pair remained flat in forex trading this morning.

 

What’s happening: Shares of Johnson & Johnson fell on Tuesday, despite the company reporting better-than-expected results for its second quarter.

What happened: Although Johnson & Johnson reported healthy profits for the quarter, it lowered its guidance for the full year citing the strength in the US dollar, which erodes the value of its global revenues.

The company reported a decline in sales in most of its segments but one of its major divisions provided support to its overall sales during the quarter.

How were the results: The New Brunswick, New Jersey-based company reported growth in sales and earnings for the second quarter.

  • Net sales rose 3% year-over-year to $24.02 billion, surpassing market expectations of $23.81 billion.
  • Adjusted earnings came in at $2.59 per share, up 4.4% year-over-year, beating the consensus estimate of $2.57 per share.

Why it matters: Johnson & Johnson managed to surpass Street expectations due to increased demand for its cancer drug and covid-19 vaccine.

The company’s covid-19 vaccine sales more than doubled from last year to $544 million, while sales of its cancer drug Darzalex came in at $1.99 billion, ahead of market expectations of $1.84 billion.

Medical Devices sales fell 1.1% to $6.89 billion, with pandemic-related mobility restrictions in some regions offsetting growth. The Consumer Health segment’s sales declined 1.3% to $3.8 billion, while Pharmaceuticals generated sales of $13.32 billion, up 6.7% in the quarter.

J&J, along with other major US multinational companies, has warned that a stronger greenback could negatively impact overseas revenues. The US dollar index, which measures the US dollar’s performance versus a basket of six major currencies, has climbed over 12% year to date and hit a two-decade high earlier this month.

Management reduced their sales guidance for fiscal 2022 from $94.8-$95.8 billion to $93.3-$94.3 billion, and the adjusted earnings projection from $10.15-$10.35 per share to $10.00-$10.10 per share.

How shares responded: Johnson & Johnson’s shares fell 1.5% to close at $171.69 on Tuesday, following the release of quarterly results. The stock has gained around 4% over the past six months.

What to watch: Investors will keep an eye on the spread of covid-19 infections. Markets will also continue monitoring the US dollar.

The markets today

Crude oil will be in focus today ahead of the EIA’s (Energy Information Administration) data on crude inventories

Context: Crude oil settled higher on Tuesday, extending gains from the previous session.

Details: Oil prices began Tuesday’s session on a negative note but recovered sharply as the session progressed. A weaker US dollar and continued supply concerns lend support to oil prices.

The US dollar index fell around 0.6% to 106.68 on Tuesday. Supply gaps are unlikely to be filled soon by output increased by the OPEC+ nations, despite the US looking to bring more crude to the market. US President Joe Biden’s visit to Saudi Arabia last week did not yield any breakthroughs for higher oil output.

However, growing fears related to a slowdown in global economic growth as the major central banks hike rates and covid-19 restrictions in China kept a lid on oil prices.

The American Petroleum Institute announced late Tuesday that said crude oil stockpiles in the country had increased by 1.860 million barrels in the week ended June 15, following a rise of 4.762 million barrels in the previous week.

WTI crude for August delivery gained $1.62 to close at $104.22 per barrel on the NYMEX on Tuesday, while September Brent crude rose $1.08 to settle at $107.35 per barrel on ICE Futures Europe. Both US and Brent oil had climbed more than 5% on Monday.

In another energy trading, August gasoline gained 4 cents to $3.31 a gallon, while August heating oil fell 3 cents to $3.63 a gallon. August natural gas declined 21 cents to $7.26 per million British thermal units on Tuesday.

What to watch: Traders await the release of the EIA’s data on crude oil stockpiles. US crude inventories had expanded by 3.254 million barrels in the week ended July 8 and are expected to rise by 0.333 million barrels in the latest week. US gasoline stockpiles are projected to decline by 0.733 million barrels, while distillate stockpiles are expected to increase by 1.2 million barrels in the recent week.

Other Markets: European trading indices closed higher on Tuesday, with the FTSE 100, DAX 40, CAC 40 and STOXX Europe 600 up by 1.01%, 2.69%, 1.79% and 1.38%, respectively.

Support & resistances for today

Technical Levels News Sentiment
EUR/USD – 1.0230 and 1.0238 Negative
AUD/USD – 0.6892 and 0.6900 Negative
Gold – 1706.66 and 1706.66 Positive
Copper – 3.2989 and 3.3084 Positive
Nasdaq 100 – 12220.65 and 12263.94 Negative

Market snapshot

Futures at 0400 (GMT)
EUR/USD (1.0237, 0.08%) Dow ($31,925, 0.42%) Brent ($106.96, -0.4%)
GBP/USD (1.2020, 0.20%) S&P500 ($3,957, 0.50%) WTI ($103.53, -0.7%)
USD/JPY (138.15, -0.03%) Nasdaq ($12,340, 0.54%) Gold ($1,709, -0.1%)

What else to watch today

UK’s inflation rate, headline rate of input prices, producer prices change and retail prices, Turkey’s consumer confidence indicator, Eurozone’s current account and consumer confidence indicator, South Africa’s inflation rate, Italy’s construction output and current account, Turkey’s total motor vehicles production and government debt, US MBA mortgage applications and existing home sales, Canada’s inflation and producer prices, Russia’s producer price inflation, China’s foreign direct investment, as well as Argentina’s balance of trade and economic activity estimator.

ADS Securities London Limited “ADSS” is an execution-only service provider. This material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or investment objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by ADSS that any particular investment, security, transaction or investment strategy is suitable for any specific person. To the extent that any content in this material is construed as investment research, you must note and accept that the content was not prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.  This material may contain links to third party websites, and any content, or use of your personal data by any third party websites is not the responsibility of ADSS or any member of the ADSS Group.


Site by Pink Green
© ADSS 2022


CFDs and Spreadbets are complex instruments and come with a high risk of losing money rapidly due to leverage. 72% of Retail investor accounts lose money when trading CFDs and Spread Bets with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

ADSS is a trading name of ADS Securities London Limited, a company registered in England and Wales with company number 07785265 (VAT Registration Number: 212722447). Registered address 9th Floor, 125 Old Broad Street, London, EC2N 1AR. ADS Securities London Limited is authorised and regulated in the UK by the Financial Conduct Authority (FRN 577453).

The information on this site is not directed at residents of the United States, Canada, EU or any particular country outside the UK, and is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law.

All opinions, news, analysis, prices or other information contained on this website are provided as general market commentary and does not constitute investment advice, nor a solicitation or recommendation for you to buy or sell any over-the-counter product or other financial instrument. Please ensure you understand all risks and seek independent advice if necessary.